Navigation Links
Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
Date:7/19/2010

of using monoamine oxidase inhibitors (MAOIs) due to potential additive effects on norepinephrine levels, which may result in adverse cardiovascular events.

Respiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation. NUCYNTA® should be administered with caution to the elderly, debilitated patients, and patients with conditions accompanied by hypoxia, hypercapnia or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, CNS depression, or coma. In such patients, even usual therapeutic doses of NUCYNTA® may increase airway resistance and decrease respiratory drive to the point of apnea. Alternative non-mu-opioid agonist analgesics should be considered and NUCYNTA® should be employed only under careful medical supervision at the lowest effective dose in such patients. If respiratory depression occurs, it should be treated as any mu-opioid agonist-induced respiratory depression.

Patients receiving other mu-opioid agonist analgesics, general anesthetics, phenothiazines, other tranquilizers, sedatives, hypnotics, or other CNS depressants (including alcohol) concomitantly with NUCYNTA® may exhibit additive CNS depression. Interactive effects resulting in respiratory depression, hypotension, profound sedation, coma or death may result if these drugs are taken in combination with NUCYNTA®. When such combined therapy is contemplated, a dose reduction of one or both agents should be considered.

Opioid analgesics can raise cerebrospinal fluid pressure as a result of respi
'/>"/>

SOURCE PriCara
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Zimmer Biomet Holdings, ... musculoskeletal healthcare, announced that it will be participating in ... at the Goldman Sachs offices in London ... About the Company Founded in 1927 and headquartered in ... a global leader in musculoskeletal healthcare.  We design, manufacture ...
(Date:8/27/2015)... , Aug. 27, 2015  CytomX Therapeutics, ... the treatment of cancer, today announced that ... the company,s Board of Directors, has been appointed ... at Eli Lilly and AstraZeneca, and also oversaw ... approved checkpoint inhibitor, at Bristol-Myers Squibb and the ...
(Date:8/27/2015)... , Aug. 27, 2015  QB3@953—a ... a University of California (UC) research institute and ... company GSK to identify and facilitate collaborations to ... benefit patients. The agreement formalizes a ... Academia (DPAc) team and creates a new channel ...
Breaking Medicine Technology:Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... Top-Line Data Expected in the Third Quarter --, ... VIAP ), a biotechnology company focused on the development ... that,it has completed the last patient visit in its ... be analyzed to determine,VIA-2291,s effect on inflammation, and the ...
... Modigene,s CTP Technology for Extending ... of Action of Therapeutic Proteins -, NES-ZIONA, Israel, ... noted the successful completion of a Phase,III clinical trial ... uses the naturally occurring CTP,peptide to extend the duration ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Modigene Platform Validated in Independent Phase III Trial of CTP Technology 2Modigene Platform Validated in Independent Phase III Trial of CTP Technology 3
(Date:8/27/2015)... ... August 27, 2015 , ... Thriveology Founders, Dr. Carly Letzt ... at The Amazing Aging Expo in Denver, Colorado on Saturday, August 29, 2015 at ... featured in media outlets as health authorities, and will present a two part seminar ...
(Date:8/27/2015)... ... ... About 10 percent of mothers experienced chronic, persistent depressive ... than 1,800 people, displacing hundreds of thousands and causing widespread damage estimated at ... most people don’t develop persistent depression after a major disaster like that, a ...
(Date:8/27/2015)... ... 27, 2015 , ... StayWell, a leading provider of patient ... ICD-10 ready and available to all clients. All Krames Patient Education content has ... more targeted and return a more comprehensive data set of content than the ...
(Date:8/27/2015)... Reading, PA (PRWEB) , ... August 27, 2015 , ... ... Therapy programs, Alvernia University now offers a third doctoral program at its main campus ... is a terminal degree program designed to prepare advanced practice nurses for the ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... a partnership agreement for quality market research promotion on the Internet. MarketPublishers.com ... Swan Analysis. , Commenting on the partnership agreement, Natalie Aster, Assistant Manager ...
Breaking Medicine News(10 mins):Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... and the Fastest Growing Healthcare Staffing Company with over 100 million Dollars ... ... Jackson Healthcare (JH) has been named the 5th largest healthcare staffing ... Compiled each year by SIA, firms are ranked on the list ...
... for their prolonged seizures with the sedative propofol may ... New research presented at CHEST 2008, the 74th annual ... Physicians (ACCP), shows that the use of propofol as ... (RSE), prolonged seizures that do not respond to initial ...
... look at the effect of neighborhood greenness on ... the Indiana University School of Medicine, Indiana University-Purdue ... that higher neighborhood greenness is associated with slower ... year period, regardless of residential density. , "Previous ...
... psychiatric cases in Michigan,s rural areas, particularly among children and ... colleges of Osteopathic Medicine and Human Medicine meet each week ... , On a typical morning, doctors in MSU,s Department of ... far away as Cadillac or Marquette all without leaving ...
... channel blockers could inhibit Plavix action, study says , , ... drugs, which are widely prescribed for coronary conditions, might ... new study says. , Calcium channel blockers appear to ... said the report by Austrian physicians published online Oct. ...
... Brachytherapy Treatment, ST. LOUIS, Oct. 27 ... to deliver radioactive seed therapy,in the prostate. The ... stabilizes the prostate during procedures. With the gland ... images to map,and confirm placement of radiation., ...
Cached Medicine News:Health News:Jackson Healthcare Named 5th Largest Healthcare Staffing Company 2Health News:Jackson Healthcare Named 5th Largest Healthcare Staffing Company 3Health News:Anti-seizure drug could be fatal 2Health News:Neighborhood greenness has long term positive impact on kids' health 2Health News:Neighborhood greenness has long term positive impact on kids' health 3Health News:MSU doctors bring much-needed psychiatric care to rural areas via technology 2Health News:Common Heart Drugs May Hamper Blood Thinner 2Health News:Common Heart Drugs May Hamper Blood Thinner 3Health News:Doctors Test Advanced Tool for Treating Prostate Cancer 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: